Answers are grounded in this paper and cite their sources.
The VPS9D1 antisense RNA1 (VPS9D1-AS1, lncRNA MYU) can act as an oncogene or an antioncogene in different malignancies.In the present study, we demonstrated that VPS9D1-AS1 is significantly upregulated in esophageal squamous cell carcinoma (ESCC) and assessed its biological function and clinical prognosis.RNA-sequencing was conducted in four pairs of ESCC tissues and normal adjacent tissues (NATs).Compared with controls, lncRNA VPS9D1-AS1 was highly expressed in ESCC tissues, cell lines and plasma.VPS9D1-AS1 upregulation significantly correlated with the histopathological grade and clinical stage of ESCC.Analyses revealed poor prognosis in ESCC patients with high VPS9D1-AS1 expression.VPS9D1-AS1 knockdown led to the inhibition of tumor proliferation, migration, and invasion in vivo and vitro.VPS9D1-AS1 silencing downregulated the Wnt/β-catenin signaling pathways by acting on key proteins such as β-catenin and c-Myc.However, the expressions of these proteins increased after the addition of pathway agonist CT99021.Therefore, taken together VPS9D1-AS1 is highly expressed in ESCC and its expression can lead to poor prognosis.In conclusion, this study suggested that VPS9D1-AS1 acts as a vital part in facilitating ESCC progression and can be a potential biomarker for the diagnosis of patients with ESCC.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: